Gelonghui October 22nd | Shaanxi Panlong Pharmaceutical (002864.SZ) stated at an investor relations event that the traditional chinese medicine industry has now entered the third batch of centralized procurement, and the company's core products are not included in this round of centralized procurement. Faced with this trend of centralized procurement, the company will proactively adapt and respond positively. On the one hand, the company will focus on cost reduction, practice diligently, and reduce energy consumption; on the other hand, the company will start with product strategy, considering expanding the number of existing 48 mainstream products to 72, and adjusting market channel strategy, with "safety compliance" as the guideline to ensure the interests of investors.